عجيب أمر شركات اللقاحات! اللقاح فعال لمتحور أوميكرون ، بعدها بكام سطر مش أكيد فاعليته بعدها بكام سطر ممكن عمل لقاح جديد خاص للمتحور في خلال 6 أسابيع! أيهم الصحيح

 

Pfizer says booster dose of vaccine protects against omicron variant

A booster dose of the Pfizer-BioNTech Covid-19 vaccine appears to provide strong protection against the omicron variant, the companies announced Wednesday.

أعلنت شركة فايزر يوم الأربعاء أن الجرعة المعززة من لقاحها بايو إن تيك كوفيد-19 يوفر حماية قوية لمتحور أوميكرون

They said a third dose of their vaccine provides a similar level of neutralizing antibodies to omicron, comparable to two doses against the original coronavirus and other variants that have emerged.

Blood samples from those who received only the primary series of the vaccine, on average, did see a 25-fold drop in antibodies against the new variant, indicating that two doses of the vaccine may not be sufficient to protect against infection with omicron.

عينات الدم التي تم أخذها من الأشخاص الذين حصلوا على اللقاح بالسلسلة الأولى له ، أظهرت أنخفاضاً في الأجسام المضادة 25 ضعفاً للمتحور الجديد ، مما يشير إلى أن الجرعتين من اللقاح قد لا تكون كافية للحماية  والوقاية من الأصابة بمتحور أوميكرون

As the highly mutated omicron variant, first identified in South Africa, spreads around the globe, scientists are racing to determine what whether the available vaccines will work against it.


The companies said the results are preliminary. The findings were detailed in a press release, and the full data have not yet been made available for other scientists to scrutinize.

But lab studies are only one piece of the puzzle. Other data are also needed to determine whether a new vaccine is needed. Scientists need to understand transmissible the omicron variant is (early indications suggest it's more contagious than the delta variant) as well as how sick it makes people (early data suggests the illness caused by the variant is milder).

المعلومات الأخرى سوف تحدد هل نحتاج  لقاح جديد

The results from Pfizer-BioNTech are the first announced by vaccine makers. Tuesday, a South Africa research institute also released lab results on how the Pfizer vaccine fared against omicron, showing about a fortyfold reduction in vaccine-induced antibodies that could neutralize the new variant. That study didn't look at booster shots, however.

Pfizer-BioNTech has previously said it could develop a variant-specific vaccine within six weeks and ship initial batches within 100 days.

وسبق أن أعلنت شركة فايزر أنها قد تقوم بتطوير لقاح محدد للمتحور خلال ستة أسابيع وتقوم بتوريد دفعات أولية خلال 100 يوم

Moderna and Johnson & Johnson are expected to release lab results from the omicron variant in the coming days. Academic research institutions are also looking into how well the vaccine works against omicron.

https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html

 

What We Know about Omicron

Infection and Spread

• How easily does Omicron spread? The Omicron variant likely will spread more easily than the original SARS-CoV-2 virus and how easily Omicron spreads compared to Delta remains unknown. CDC expects that anyone with Omicron infection can spread the virus to others, even if they are vaccinated or don’t have symptoms.
• من المحتمل أن ينتشر متحور اوميكرون بسهولة أكبر من فيروس كوفيد-19 الأصلي وبالنسبة لمدى سهولة أنتشار أوميكرون مقارنة ب متحور دلتا، لازال غير معروف للعلماء، ويتوقع مركز التحكم والسيطرة على الأمراض أن آي شخص مصاب بعدوى اوميكرون يمكن أن ينشر الفيروس للأخرين حتى لمن حصل على التطعيمين أو من لا يظهر عليه أعراض

• Will Omicron cause more severe illness? More data are needed to know if Omicron infections, and especially reinfections and breakthrough infections in people who are fully vaccinated, cause more severe illness or death than infection with other variants.
• هناك حاجة للمزيدمن المعلومات والبيانات لمعرفة ما إذا كانت عدوى أميكرون العدوى والإصابات في الأشخاص الذين تم تطعيمهم تسبب مرضاً شديداً أو وفاة بطريقة أكبر من المتحورات السابقة
• Will vaccines work against Omicron? Current vaccines are expected to protect against severe illness, hospitalizations, and deaths due to infection with the Omicron variant. However, breakthrough infections in people who are fully vaccinated are likely to occur. With other variants, like Delta, vaccines have remained effective at preventing severe illness, hospitalizations, and death. The recent emergence of Omicron further emphasizes the importance of vaccination and boosters.
• Will treatments work against Omicron? Scientists are working to determine how well existing treatments for COVID-19 work. Based on the changed genetic make-up of Omicron, some treatments are likely to remain effective while others may be less effective.
• هل ستكون العلاجات واللقاحات الحالية فعالة مع متحور أميكرون؟
• مازال العلماء يعملون على تحديد مدى نجاح العلاجات الحالية ل كوفيد-19 بناءً على التركيب الجيني المتغير لاوميكرون ، ومن المرجح أن تظل بعض تلك العلاجات فعالة بينما قد يكون البعض الآخر أقل فاعلية. ومن عندي أول لا فاعليه لها على الإطلاق

We have the Tools to Fight Omicron

Vaccines remain the best public health measure to protect people from COVID-19, slow transmission, and reduce the likelihood of new variants emerging. COVID-19 vaccines are highly effective at preventing severe illness, hospitalizations, and death. Scientists are currently investigating Omicron, including how protected fully vaccinated people will be against infection, hospitalization, and death. CDC recommends that everyone 5 years and older protect themselves from COVID-19 by getting fully vaccinated. CDC recommends that everyone ages 18 years and older should get a booster shot at least two months after their initial J&J/Janssen vaccine or six months after completing their primary COVID-19 vaccination series of Pfizer-BioNTech or Moderna.

Masks offer protection against all variants. CDC continues to recommend wearing a mask in public indoor settings in areas of substantial or high community transmission, regardless of vaccination status. CDC provides advice about masks for people who want to learn more about what type of mask is right for them depending on their circumstances.

Tests can tell you if you are currently infected with COVID-19. Two types of tests are used to test for current infection: nucleic acid amplification tests (NAATs) and antigen tests. NAAT and antigen tests can only tell you if you have a current infection. Individuals can use the COVID-19 Viral Testing Tool to help determine what kind of test to seek. Additional tests would be needed to determine if your infection was caused by Omicron. Visit your state, tribal, local, or territorial health department’s website to look for the latest local information on testing.

Self-tests can be used at home or anywhere, are easy to use, and produce rapid results. If your self-test has a positive result, stay home or isolate for 10 days, wear a mask if you have contact with others, and call your healthcare provider. If you have any questions about your self-test result, call your healthcare provider or public health department.

Until we know more about the risk of Omicron, it is important to use all tools available to protect yourself and others.

What CDC is Doing to Learn about Omicron

Virus Characteristics

CDC scientists are working with partners to gather data and virus samples that can be studied to answer important questions about the Omicron variant. Scientific experiments have already started. CDC will provide updates as soon as possible.

Variant Surveillance

In the United States, CDC uses genomic surveillance to track variants of SARS-CoV-2, the virus that causes COVID-19 to more quickly identify and act upon these findings to best protect the public’s health. CDC established multiple ways to connect and share genomic sequence data being produced by CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible databases maintained by the National Center for Biotechnology Informationexternal icon (NCBI) and the Global Initiative on Sharing Avian Influenza Dataexternal icon (GISAID). CDC’s national genomic surveillance can detect a variant that is circulating at 0.1% frequency with 99% statistical confidence.